Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MONAMI
2024-511857-23-00Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of monalizumab and volrustomig in cancer, sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoints: Dose-limiting toxicities (DLTs) during safety lead-in, Adverse events during safety lead-in and 3 more. Started Nov 2024; status: completed.
02
Drugs
monalizumabvolrustomig
03
Conditions
cancer
Beyond the preview
Go deeper on 2024-511857-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511857-23-00.